With the UK’s default to leave the EU without a deal, there are a number of steps businesses in the life sciences sector should take to prepare. Many companies in the sector are faced with simultaneously navigating an increasingly complex regulatory environment while trying to mitigate as much as possible the significant impact of Brexit – including the effects of weak drug development pipelines, access to talent, supply chain disruption and potentially reduced research and development (R&D) funding.